01.06.2023

SPS 2023

When: 18.09. – 21.09.2023

Venue: SQUARE Brussels Meeting Centre, Brussels, Belgium.

Go to the Conference website here.

 

Meet the Nanion Team at SPS

Join Niels Fertig, Sonja Feix-Stölzle, Rodolfo Haedo and Ronald Knox at booth #208 to learn about our CiPA certified platforms and how we can help you accelerate your research.

We will be present with our new system AtlaZ, for quantitative cell analytics impedance, as well as with the FLEXcyte 96. Do not hesitate to stop by our booth to learn about the capabilities of our instruments.

Nanion will be present at the Poster session

  •  “Development of a high-throughput system for advanced functional cell analysis to predict safety”.

Poster #120, presented by Sonja Feix-Stölzle

  • “Experimental and technical best practice considerations for effective high throughput recordings of cardiac ion channels”.

Poster #041, presented by Rodolfo Haedo

  • “Application of hiPSC-derived Nociceptors on an Automated Patch Clamp System for Mechanism of Action-based De-risking of Neuronal Toxicity”.

Poster #122, presented by Ronald Knox

  • “In Vitro Systems for the Assessment of Chronic Cardiotoxic Effects: News from the HESI Stem Cell Working Group”.

            Poster #095, presented by Bettina Lickiss (innoVitro) from a collaboration with innoVitro and Axol Bioscience.

  • “Modeling of Dynamic Drug-HERG Channel Interactions Reproducing Preferential State-Dependent Binding and Trapping Properties Using Simple Voltage Clamp Protocols and an Automated High-Throughput System”.

Poster #TBD, presented by Lucia Romero

Partner Sponsored talk

Talk: “Comprehensive in vitro human models for assessing drug-induced cardiotoxicity”.

When: Wednesday, September 20th, from 12:30 -13:30 CET.

Location: Studio 212

 

Summary:

This joint partner session will focus on the characterization of drug effects on human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM). The use of these cell models continues to increase in the assessment of cardiac safety and toxicological side effects of newly developed compounds, due to their reproducibility and low ethical concern.   However, the obstacles presented from using a 2D culture system, immature cellular phenotypes, or serum-containing media for chronic dosing assays raise concerns over potential non-physiological responses in preclinical drug development and safety. Here, we will introduce solutions to these hurdles by using innovative pro-maturation technologies in 2D and 3D specialized cell culture conditions and newly developed protocols for recording cardiac activity.    Characterization, pro-maturation, and toxicity assays using iCell Cardiomyocytes2 for automated patch clamp (Patchliner Dynamite) and contractile force recordings (FLEXcyte 96) in mono and co-culture with human iPSC- derived iCell Cardiac fibroblasts will be presented.

Oral presentations

Talk: “Contractility‐Based Pharmacological Characterization of hiPSC‐Derived Atrial and Ventricular Cardiomyocytes Assessed on the FLEXcyte 96”

Presenter: Bettina Lickiss (innoVitro)

When: Tuesday, September 19, 1:45 pm – 2 pm. Session 2 In Vitro Cardiovascular